47.63
2.65%
1.23
시간 외 거래:
47.63
전일 마감가:
$46.40
열려 있는:
$47.22
하루 거래량:
228.96K
Relative Volume:
0.75
시가총액:
$3.00B
수익:
-
순이익/손실:
$-54.80M
주가수익비율:
-40.74
EPS:
-1.1692
순현금흐름:
$-64.65M
1주 성능:
-1.16%
1개월 성능:
-13.84%
6개월 성능:
+5.24%
1년 성능:
-7.12%
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-02-15 | 개시 | Wolfe Research | Outperform |
2023-12-08 | 개시 | Citigroup | Buy |
2023-11-02 | 개시 | Stifel | Buy |
2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
2023-08-31 | 개시 | Needham | Buy |
2023-06-15 | 개시 | Barclays | Equal Weight |
2023-05-01 | 개시 | Guggenheim | Buy |
2023-03-22 | 개시 | Wedbush | Outperform |
2023-03-09 | 개시 | BTIG Research | Buy |
2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
2023-02-02 | 개시 | Bryan Garnier | Buy |
2022-11-11 | 개시 | Jefferies | Buy |
2022-08-25 | 개시 | SVB Leerink | Outperform |
2022-07-21 | 개시 | H.C. Wainwright | Buy |
2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
Wedbush Reiterates Outperform Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
14,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by AlphaCentric Advisors LLC - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
Congress Asset Management Co. Makes New Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN
I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St
(MLTX) Proactive Strategies - Stock Traders Daily
HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares - Investing.com India
MoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by HC Wainwright - MarketBeat
MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold (NASDAQ:MLTX) - Seeking Alpha
When (MLTX) Moves Investors should Listen - Stock Traders Daily
MoonLake Immunotherapeutics [MLTX] stock for 100,003,200 USD was sold by BVF PARTNERS L P/IL - Knox Daily
MLTX’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing MoonLake Immunotherapeutics (MLTX)’s Performance - The Dwinnex
What is MLTX’s price-to-sales ratio telling us about the company’s value? - US Post News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down on Insider Selling - Defense World
Millennium Management LLC Has $9.54 Million Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Biotechnology value fund L P executives sell over $100 million in MoonLake Immunotherapeutics shares - Investing.com India
MoonLake Immunotherapeutics director sells shares worth over $9m - Investing.com
Insider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 171,000 Shares of Stock - Defense World
Simon Sturge Sells 171,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
MoonLake Immunotherapeutics director sells shares worth over $9m By Investing.com - Investing.com UK
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 8.3%Here's What Happened - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Position Increased by The Manufacturers Life Insurance Company - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
MLTX’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
How the (MLTX) price action is used to our Advantage - Stock Traders Daily
MoonLake Immunotherapeutics' SWOT analysis: stock outlook amid clinical trials - Investing.com
Marshall Wace LLP Has $48.31 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Marshall Wace LLP - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 5.8% - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Fred Alger Management LLC - Defense World
MoonLake Immunotherapeutics (MLTX) – Research Analysts’ Recent Ratings Updates - Defense World
MoonLake Immunotherapeutics to Post FY2024 Earnings of ($1.37) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:MLTX) - Defense World
Brokers Issue Forecasts for MoonLake Immunotherapeutics' FY2024 Earnings (NASDAQ:MLTX) - MarketBeat
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? - Insider Monkey
Logos Global Management LP Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
750,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by Logos Global Management LP - MarketBeat
Integral Health Asset Management LLC Sells 200,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
10 Best Guru Stocks To Buy Now - Insider Monkey
Integral Health Asset Management LLC Has $9.67 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
HighVista Strategies LLC Lowers Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
Santos da Silva Jorge | Chief Executive Officer |
Feb 27 '24 |
Sale |
55.00 |
62,810 |
3,454,550 |
3,043,619 |
Santos da Silva Jorge | Chief Executive Officer |
Feb 28 '24 |
Sale |
55.00 |
56,065 |
3,083,575 |
2,987,554 |
Santos da Silva Jorge | Chief Executive Officer |
Feb 29 '24 |
Sale |
55.89 |
4,740 |
264,919 |
2,982,814 |
Reich Kristian | Chief Scientific Officer |
Feb 28 '24 |
Sale |
55.00 |
31,910 |
1,755,050 |
2,925,573 |
Reich Kristian | Chief Scientific Officer |
Feb 27 '24 |
Sale |
55.00 |
29,491 |
1,622,005 |
2,957,483 |
Reich Kristian | Chief Scientific Officer |
Feb 27 '24 |
Sale |
55.00 |
29,431 |
1,618,705 |
70,071 |
Reich Kristian | Chief Scientific Officer |
Feb 28 '24 |
Sale |
55.00 |
28,090 |
1,544,950 |
41,981 |
Santos da Silva Jorge | Chief Executive Officer |
Feb 21 '24 |
Sale |
55.27 |
1,125 |
62,179 |
3,106,429 |
Reich Kristian | Chief Scientific Officer |
Feb 20 '24 |
Sale |
57.45 |
10,000 |
574,500 |
2,987,483 |
자본화:
|
볼륨(24시간):